Summary
The OPCRDA contains Australian Primary Care data across NSW, QLD, Victoria, and South Australia. Varied urban/rural and SES for contributing sites.
The Optimum Patient Care Research Database Australia (OPCRDA) is a nonprofit, ethically governed research database managed by Optimum Patient Care Australia Pty Ltd (OPCA), a social enterprise supporting healthcare providers across Australia.
OPCRDA collects de-identified Electronic Medical Records (EMR) patient data from GP practices and respiratory and allergy specialist practices across Australia (over 1 million patients). EMR data are supplemented with patient-reported information/outcome data in a subgroup of patients. OPCRDA includes information on prescriptions, medical devices, procedures, clinical measurements, healthcare provider details, biomarker data, patient-reported outcomes, lifestyle factors, and sociodemographic information.
The database covers main Australian clinical systems such as Best Practice and Medical Director. Its primary uses include public health research, healthcare quality improvement, and feasibility studies for clinical trials. Data access is governed by the Anonymous Data Ethics Protocols and Transparency (ADEPT) committee.
OPCRDA collects longitudinal, de-identified electronic medical records from both GPs and specialist practices across Australia. It includes information on prescriptions, medical devices, procedures, clinical measurements, healthcare provider details, biomarker data, patient-reported outcomes, lifestyle factors, and sociodemographic information.
(-Derived from EMR systems inlcuding Medical Director and Best Practice;
-PRIO data from a select sub group of patients)
[Median time between first and last available records for unique individuals: 5.54 years;
Median time between first and last available records for unique active individuals (alive and currently registered): 4.70 years.]
(Contains primary care data, respiratory and allergy specialist care data. Contains inpatient, outpatient and ER data that can be sent back to the GP.)
The Optimum Patient Care Research Database Australia (OPCRDA) is updated on an ongoing basis.
This profile was developed for the B.R.I.D.G.E. TO DATA site on July 22, 2025.
Population Dynamics
(No exact number)
(Not applicable)
Not applicable, since data are still being collected
Demographic Data
Age/YOB is collected
< 18 years: ~8.3%
> 65 years: ~17.6%
(Percentage based on current, most recent data)
Males = ~40.7%
Females = ~55%
(White, Asian, African, Mixed, Other, Unknown)
Australia
The OPCRDA contains Australian Primary Care data across NSW, QLD, Victoria, and South Australia, Western Australia and Australian Capital Territory. Varied urban/rural and SES for contributing sites.
(Year of birth)
Death is an event that triggers de-registration of a person in the data source.
NOTE: It is known if a patient has died if recorded by the general practitioner in the patient records.
(Not applicable)
OPCRDA captures Social Determinants of Health information (e.g., lifestyle, education, access to healthcare, etc.) from a subgroup of PRIO patients. Socio-economic information for the location of the GP site the patient attends via proxies, such as deprivation data based on postcode of the GP site (also data from questionnaires and clinical reviews).
Physician & Practioner Info
Diagnoses/Signs & Symptoms
[Best Practice and Medical Director internal EMR codes (Pyefinch and DOCLE)
Best Practice (BP) and MedicalDirector (MD) codes are internal identifiers used by Australian general practice EMR systems to record clinical terms such as diagnoses, medications, test results, and encounters. Each code corresponds to a clinical concept and may be mapped to standard terminologies like SNOMED CT-AU, ICPC-2 Plus, or AMT.]
(All patient history, from beginning to the present time)
OPCRDA captures height, weight, BMI, allergies, etc.
However, only if coded by the healthcare practitioner
Information on lung cancer is retrieved from clinical notes, i.e., searching for practice-system specific lung cancer codes and free-text search terms in clinical notes.
Information is available on smoking status (current smoker, ex-smoker, never smoked), and alcohol intake
Procedures
[Best Practice and Medical Director internal EMR codes (Pyefinch and DOCLE)]
Drug Information
Dose and Route of administration are both known
Brand names and active ingredients are available for drugs
Dosage regimen is known
EMR data do not include whether the drug was dispensed by the patient at the pharmacist; however they have prescribing instructions from the doctor which can specify the number of days the GP has written the script for.
(PBS codes.
PBS codes are identifiers assigned to medicines listed on the Australian Government’s Pharmaceutical Benefits Scheme (PBS). Each code uniquely represents a specific medication, dosage form, and strength that is subsidised under the scheme. These codes are used in prescribing, dispensing, and health data systems to track medication use and reimbursement.)
Biobanks
Genetic-PGx Data
Economic Data
(Not applicable)
(Not applicable)
(Not applicable)
(Not applicable)
Validation & Linkage
If requested, validity of the data within OPCRDA can be verified against the original medical charts.
Researchers cannot access the original medical records held at the GP site.
NOTE: OPCRDA is not linked to other external databases but has the capacity to be linked to other datasets. Also, while not at the moment, they are looking to have it in OMOP in future.
N/A
(Not applicable)
Administrative Information
Optimum Patient Care Australia Pty Ltd (OPCA)
320 Adelaide Street
Brisbane City, Level 10, Office 1
AUSTRALIA
Email: info@optimumpatientcare.org.au
Phone: (+61) 405 764 842
Fax: (+61) 7 3036 6729
Complete the Contact Us form at
https://www.optimumpatientcare.org.au/opcrda
(Funding by own institution)
(Not applicable)
N/A
(Not applicable)
Prices vary based on the project scope. Please contact info@optimumpatientcare.org.au for more information.
(An anonymised study dataset is created according to requested study requirements and data specification either as an analytical dataset or in a raw relational database format.)
1. Price D, Jenkins C, Hancock K, Vella R, Heraud F, Le Cheng P, Murray R, Beekman M, Bosnic-Anticevich S, Botini F, Carter V, Catanzariti A, Doan J, Fletton K, Kichkin A, Le T, Le Lievre C, Lau CM, Novic D, Pakos J, Ranasinghe K, Roussos A, Samuel-King J, Sharma A, Stewart D, Willet B, Bateman E; OPCA Improving Asthma Outcomes in Australia Research Group. The Association Between Short-Acting β2-Agonist Over-Prescription, and Patient-Reported Acquisition and Use on Asthma Control and Exacerbations: Data from Australia. Adv Ther. 2024 Mar;41(3):1262-1283.
2. Hancock KL, Bosnic-Anticevich S, Blakey JD, Hew M, Chung LP, Cvetkovski B, Claxton S, Del Fante P, Denton E, Doan J, Ranasinghe K, Morgan L, Sharma A, Smith PK, Stewart D, Thompson PJ, Wiseman R, Upham JW, Yan KY, Carter V, Dhillon K, Heraud F, Le T, Vella R, Price D; OPCA Improving Asthma outcomes in Australia Research Group. Characterisation of the Australian Adult Population Living with Asthma: Severe - Exacerbation Frequency, Long-Term OCS Use and Adverse Effects. Pragmat Obs Res. 2022 Jul 5;13:43-58.
3. Bateman ED, Price DB, Wang HC, Khattab A, Schonffeldt P, Catanzariti A, van der Valk RJP, Beekman MJHI. Short-acting β2-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study. Eur Respir J. 2022 May 5;59(5):2101402.
4. Evans A, Soremekun S, Stanley B, Appiagyei F, Couper A, Taylor O, Le T, Pullen R, Jones S, Carter V, Price C. Strategies that promote sustainability in quality improvement activities for chronic disease management in healthcare settings: a practical perspective. Quality in Primary Care. 2020;28(6), 55–60.
Database Contact
Optimum Patient Care Australia Pty Ltd (OPCA)
320 Adelaide Street
Brisbane City, Level 10, Office 1
AUSTRALIA
Email: info@optimumpatientcare.org.au
Phone: (+61) 405 764 842
Fax: (+61) 7 3036 6729
Complete the Contact Us form at
https://www.optimumpatientcare.org.au/opcrda
Literature References
1. Price D, Jenkins C, Hancock K, Vella R, Heraud F, Le Cheng P, Murray R, Beekman M, Bosnic-Anticevich S, Botini F, Carter V, Catanzariti A, Doan J, Fletton K, Kichkin A, Le T, Le Lievre C, Lau CM, Novic D, Pakos J, Ranasinghe K, Roussos A, Samuel-King J, Sharma A, Stewart D, Willet B, Bateman E; OPCA Improving Asthma Outcomes in Australia Research Group. The Association Between Short-Acting β2-Agonist Over-Prescription, and Patient-Reported Acquisition and Use on Asthma Control and Exacerbations: Data from Australia. Adv Ther. 2024 Mar;41(3):1262-1283.
2. Hancock KL, Bosnic-Anticevich S, Blakey JD, Hew M, Chung LP, Cvetkovski B, Claxton S, Del Fante P, Denton E, Doan J, Ranasinghe K, Morgan L, Sharma A, Smith PK, Stewart D, Thompson PJ, Wiseman R, Upham JW, Yan KY, Carter V, Dhillon K, Heraud F, Le T, Vella R, Price D; OPCA Improving Asthma outcomes in Australia Research Group. Characterisation of the Australian Adult Population Living with Asthma: Severe - Exacerbation Frequency, Long-Term OCS Use and Adverse Effects. Pragmat Obs Res. 2022 Jul 5;13:43-58.
3. Bateman ED, Price DB, Wang HC, Khattab A, Schonffeldt P, Catanzariti A, van der Valk RJP, Beekman MJHI. Short-acting β2-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study. Eur Respir J. 2022 May 5;59(5):2101402.
4. Evans A, Soremekun S, Stanley B, Appiagyei F, Couper A, Taylor O, Le T, Pullen R, Jones S, Carter V, Price C. Strategies that promote sustainability in quality improvement activities for chronic disease management in healthcare settings: a practical perspective. Quality in Primary Care. 2020;28(6), 55–60.